• Researchers Identify Enzyme as New Target for Treating Classical Hodgkin’s Lymphoma
  • FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma
  • Incysus Advances T-Cell Therapy into Phase 1 Trial for Blood Cancers
  • Primary Care Programs for Cancer Survivors Are Still Lacking, Report Reveals
  • Remetinostat’s Promising Results in Mycosis Fungoides Patients Presented at EORTC Meeting
  • Four Patients Complete Treatment in Phase 2 Trial of OXS-1550 as Lymphoma and Leukemia Treatment
  • Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants
  • CAR T-cells Targeting CD20-positive Non-Hodgkin’s Lymphoma Safe and Effective, Long-term Study Shows
  • Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds
  • Adcetris Induced Durable, Long-term Remission in Nearly Half of Large Cell Lymphoma Patients in Phase 2 Trial
  • CCRM and Affigen Partner to Develop Personalized Therapeutics for B-Cell Lymphoma, Leukemia
  • Lymphoma Scare Turned Out to Be a Reaction to Tattoo Ink, Case Study Reports